Filing Details
- Accession Number:
- 0001615774-15-000552
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-03-24 16:19:24
- Reporting Period:
- 2015-03-20
- Filing Date:
- 2015-03-24
- Accepted Time:
- 2015-03-24 16:19:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1266806 | Second Sight Medical Products Inc | EYES | Electromedical & Electrotherapeutic Apparatus (3845) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1625594 | J. Robert Greenberg | 12744 San Fernando Road, Bldg. 3 Sylmar CA 91342 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-03-20 | 98,742 | $13.28 | 224,922 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-03-23 | 1,258 | $13.40 | 223,664 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Option(b) | $4.25 | 2017-01-01 | 125,000 | 125,000 | Direct | |
Common Stock | Option(c) | $4.75 | 2015-09-01 | 150,000 | 150,000 | Direct | |
Common Stock | Option(d) | $4.75 | 2016-01-01 | 17,969 | 17,969 | Direct | |
Common Stock | Option(e) | $5.00 | 2016-05-01 | 8,223 | 8,223 | Direct | |
Common Stock | Option(f) | $5.00 | 2017-01-01 | 30,625 | 30,625 | Direct | |
Common Stock | Option(g) | $5.00 | 2018-02-01 | 23,750 | 23,750 | Direct | |
Common Stock | Option(h) | $5.00 | 2018-11-01 | 150,000 | 150,000 | Direct | |
Common Stock | Option(i) | $5.00 | 2019-02-01 | 23,750 | 23,750 | Direct | |
Common Stock | Option(j) | $5.00 | 2020-02-01 | 53,125 | 53,125 | Direct | |
Common Stock | Option(k) | $5.00 | 2020-02-01 | 50,625 | 50,625 | Direct | |
Common Stock | Option(l) | $5.00 | 2021-03-01 | 41,563 | 41,563 | Direct | |
Common Stock | Option(m) | $5.00 | 2022-03-01 | 29,063 | 29,063 | Direct | |
Common Stock | Option(n) | $5.00 | 2024-04-01 | 11,718 | 11,718 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2017-01-01 | 125,000 | 125,000 | Direct |
2015-09-01 | 150,000 | 150,000 | Direct |
2016-01-01 | 17,969 | 17,969 | Direct |
2016-05-01 | 8,223 | 8,223 | Direct |
2017-01-01 | 30,625 | 30,625 | Direct |
2018-02-01 | 23,750 | 23,750 | Direct |
2018-11-01 | 150,000 | 150,000 | Direct |
2019-02-01 | 23,750 | 23,750 | Direct |
2020-02-01 | 53,125 | 53,125 | Direct |
2020-02-01 | 50,625 | 50,625 | Direct |
2021-03-01 | 41,563 | 41,563 | Direct |
2022-03-01 | 29,063 | 29,063 | Direct |
2024-04-01 | 11,718 | 11,718 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.95, inclusive. The reporting person undertakes to provide to the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These transactions were effected pursuant to planned sales under lock-up agreement entered into at the time of EYES IPO in November 2014, as approved by Board of EYES and the IPO underwriter.
- The price reported in Column 4 is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.52 inclusive. The reporting person undertakes to provide to the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. These transactions were effected pursuant to planned sales under lock-up agreement entered into at the time of EYES IPO in November 2014, as approved by Board of EYES and the IPO underwriter.
- These are vested employee options currently exercisable.
- These options will vest and become exercisable within the next 60 days